TABLE 1.
Number of ACR20/50 Responders and Predicted Costs over 2 Years for MTX-IR Patients, with Switch Criteria Based on ACR20/50 Responses Without Rebatea
| 100% Monotherapy (n = 1,321) | 50% Monotherapy and 50% Combination Therapy (n = 1,321) | |||||
|---|---|---|---|---|---|---|
| Tofacitinib→ABA→RTX | ADA→ABA→RTX | ETN→ABA→RTX | Tofacitinib→ABA→RTX | ADA→ABA→RTX | ETN→ABA→RTX | |
| A. Switch Criteria Based on ACR20 Response | ||||||
| Responders, n | ||||||
| ACR20 | 1,086 | 917 | 1,012 | 1,007 | 967 | 1,046 |
| ACR50 | 617 | 404 | 623 | 581 | 506 | 605 |
| Total 2-year costs, $ | 149,677,072 | 172,449,974 | 177,640,640 | 151,347,506 | 175,635,131 | 180,289,525 |
| Drug costs | 144,274,723 | 166,187,200 | 172,165,870 | 144,767,326 | 169,010,029 | 174,341,811 |
| Administration costs | 3,127,826 | 4,369,427 | 3,745,342 | 3,442,784 | 3,815,019 | 3,345,974 |
| Monitoring costs | 1,471,559 | 774,279 | 744,797 | 2,327,175 | 1,668,332 | 1,610,240 |
| ADR costs | 802,963 | 1,119,068 | 984,631 | 810,221 | 1,141,752 | 991,499 |
| Cost PMPM, $ | 6.24 | 7.19 | 7.40 | 6.31 | 7.32 | 7.51 |
| Cost per, $: | ||||||
| ACR20 responder | 137,810 | 188,141 | 175,595 | 150,283 | 181,678 | 172,416 |
| ACR50 responder | 242,738 | 426,805 | 285,115 | 260,496 | 347,203 | 297,946 |
| B. Switch Criteria Based on ACR50 Response | ||||||
| Responders, n | ||||||
| ACR20 | 1,290 | 1,118 | 1,164 | 1,175 | 1,146 | 1,225 |
| ACR50 | 693 | 480 | 681 | 654 | 584 | 683 |
| Total 2-year costs, $ | 148,742,827 | 165,074,100 | 171,623,677 | 150,164,185 | 168,551,333 | 172,742,731 |
| Drug costs | 141,596,905 | 156,950,623 | 164,710,210 | 141,891,304 | 160,029,667 | 164,914,514 |
| Administration costs | 4,959,095 | 6,231,257 | 5,157,437 | 5,116,195 | 5,616,377 | 5,093,419 |
| Monitoring costs | 1,372,056 | 839,134 | 794,029 | 2,338,011 | 1,829,155 | 1,772,708 |
| ADR costs | 814,771 | 1,053,085 | 962,001 | 818,674 | 1,076,134 | 962,089 |
| Cost PMPM, $ | 6.20 | 6.88 | 7.15 | 6.26 | 7.02 | 7.20 |
| Cost per, $: | ||||||
| ACR20 responder | 115,316 | 147,687 | 147,475 | 127,825 | 147,021 | 141,059 |
| ACR50 responder | 214,500 | 343,751 | 252,146 | 229,687 | 288,667 | 253,044 |
Note: These data are based on a previously published economic model analyzing tofacitinib as a second-line treatment in MTX-IR patients.19 The previously published model was updated according to recent medication price increases and expanded to include switching criteria, as shown in this table.
aThis table shows the number of ACR20/50 responders and costs PMPM and per ACR responder for MTX-IR patients receiving tofacitinib 5 mg BID as second-line treatment directly after MTX, compared with ADA and ETN, without rebates.
ABA = abatacept; ACR = American College of Rheumatology; ADA = adalimumab; ADR = adverse drug reaction; BID = twice daily; ETN = etanercept; MTX = methotrexate; MTX-IR = methotrexate-inadequate responder; PMPM = per member per month; RTX = rituximab.